External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population

被引:6
|
作者
Asgari, Samaneh [1 ]
Moosaie, Fatemeh [1 ,2 ]
Khalili, Davood [1 ,3 ]
Azizi, Fereidoun [4 ]
Hadaegh, Farzad [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Prevent Metab Disorders Res Ctr, Res Inst Endocrine Sci, Tehran, Iran
[2] Univ Tehran Med Sci, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Biostat & Epidemiol, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, Tehran, Iran
关键词
Risk assessment; External validation; Cardiovascular disease; Diabetes mellitus; type; 2; Chronic kidney disease; CARDIOVASCULAR-DISEASE; SCREENING TOOL; FOLLOW-UP; PERFORMANCE; PREVALENCE; PREDICTION; PROFILE; MODELS; VALUES;
D O I
10.1186/s12967-020-02434-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background High burden of chronic cardio-metabolic disorders including type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD) have been reported in the Middle East and North Africa region. We aimed to externally validate a non-laboratory risk assessment tool for the prediction of the chronic cardio-metabolic disorders in the Iranian population. Methods The predictors included age, body mass index, waist circumference, use of antihypertensive medications, current smoking, and family history of cardiovascular disease and/or diabetes. For external validation of the model in the Tehran lipids and glucose study (TLGS), the Area under the curve (AUC) and the Hosmer-Lemeshow (HL) goodness of fit test were performed for discrimination and calibration, respectively. Results Among 1310 men and 1960 women aged 28-85 years, 29.5% and 47.4% experienced chronic cardio-metabolic disorders during the 6 and 9-year follow-up, respectively. The model showed acceptable discrimination, with an AUC of 0.72 (95% CI 0.69-0.75) for men and 0.73 (95% CI 0.71-0.76) for women. The calibration of the model was good for both genders (min HL P = 0.5). Considering separate outcomes, AUC was highest for CKD (0.76 (95% CI 0.72-0.79)) and lowest for T2DM (0.65 (95% CI 0.61-0.69)), in men. As for women, AUC was highest for CVD (0.82 (95% CI 0.78-0.86)) and lowest for T2DM (0.69 (95% CI 0.66-0.73)). The 9-year follow-up demonstrated almost similar performances compared to the 6-year follow-up. Using Cox regression in place of logistic multivariable analysis, model's discrimination and calibration were reduced for prediction of chronic cardio-metabolic disorders; the issue which had more effect on the prediction of incident CKD among women. Moreover, adding data of educational levels and marital status did not improve, the discrimination and calibration in the enhanced model. Conclusion This model showed acceptable discrimination and good calibration for risk prediction of chronic cardio-metabolic disorders in short and long-term follow-up in the Iranian population.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study
    Tehrani, Fahimeh Ramezani
    Montazeri, Seyed Ali
    Hosseinpanah, Farhad
    Cheraghi, Leila
    Erfani, Hadi
    Tohidi, Maryam
    Azizi, Fereidoun
    PLOS ONE, 2015, 10 (09):
  • [42] Associations of leucocyte telomere length with cardio-metabolic risk profile in a South African HIV-infected population
    Ngwa, Ndonwi Elvis
    Peer, Nasheeta
    Matsha, Tandi E.
    de Villiers, Anniza
    Sobngwi, Eugene
    Kengne, Andre P.
    MEDICINE, 2022, 101 (05) : E28642
  • [43] Prenatal smoking exposure and cardio-metabolic risk factors in adulthood: a general population study and a meta-analysis
    Yachana Kataria
    Lyvia Gaewsky
    Christina Ellervik
    International Journal of Obesity, 2019, 43 : 763 - 773
  • [44] Influence of ethnicity and gene polymorphisms of adiponectin on the factors of cardio-metabolic risk in a population of type 2 diabetes in the West
    Ezourhi, N.
    Foucan, L.
    Maimaitiming, S.
    Inamo, J.
    Hedreville, S.
    Atallah, A.
    Deloumeaux, J.
    Kangambega, P.
    Donnet, J. P.
    Marre, M.
    Fumeron, F.
    DIABETES & METABOLISM, 2009, 35 : A37 - A38
  • [45] INTERACTION OF PLASMA HOMOCYSTIENE, RENAL FUNCTION AND CARDIO-METABOLIC RISK FACTORS- AN OBSERVATION IN A RURAL POPULATION OF BANGLADESH
    Rahman, Md. Hafizur
    Alam, Kazi Shahnoor
    Alam, Babrul
    Banerjee, Sajal Krishna
    Chaudhury, S. R.
    Arslan, M. I.
    Hassan, M. S.
    Chowdhury, M. A. A.
    Iqbal, Md M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 : 324 - 324
  • [46] Sleep quality in middle-aged and elderly Chinese: distribution, associated factors and associations with cardio-metabolic risk factors
    Nazanin Haseli-Mashhadi
    Tony Dadd
    An Pan
    Zhijie Yu
    Xu Lin
    Oscar H Franco
    BMC Public Health, 9
  • [47] The effects of two exercise therapy methods on cardio-metabolic risk factors in diabetic overweight middle-aged females
    Kaviani, M.
    Banitalebi, E.
    Abbasi, A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 124 - 124
  • [48] Who is at risk of chronic disease? Associations between risk profiles of physical activity, sitting and cardio-metabolic disease in Australian adults
    Engelen, Lina
    Gale, Joanne
    Chau, Josephine Y.
    Hardy, Louise L.
    Mackey, Martin
    Johnson, Nathan
    Shirley, Debra
    Bauman, Adrian
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2017, 41 (02) : 178 - 183
  • [49] ASSESSMENT OF NUTRITIONAL STATUS IN OBESE CHILDREN DURING A 10 YEARS FOLLOW-UP AND CARDIO-METABOLIC RISK
    Andreoli, Angela
    Pitaro, Eugenio
    Neri, Anna
    Rizza, Stefano
    Sorge, Roberto
    Petrilli, Arianna
    Bitti, Manca Maria Luisa
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 488 - 488
  • [50] Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease
    Hosseini S.A.
    Alipour M.
    Sarvandian S.
    Haghighat N.
    Bazyar H.
    Aghakhani L.
    BMC Endocrine Disorders, 24 (1)